Effect of Dapagliflozin on Urinary Albumin Excretion in Patients With CKD With and Without T2D
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Lancet Diabetes Endocrinol 2021 Oct 04;[EPub Ahead of Print], N Jongs, T Greene, GM Chertow, JJV McMurray, AM Langkilde, R Correa-Rotter, P Rossing, CD Sjöström, BV Stefansson, RD Toto, DC Wheeler, HJL HeerspinkFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.